Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model
Open Access
- 30 November 2007
- journal article
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 120 (5), 1146-1152
- https://doi.org/10.1016/j.jaci.2007.07.055
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Cost‐effectiveness of omalizumab in patients with severe persistent allergic asthmaAllergy, 2007
- Cost-effectiveness of inhaled steroids in asthma: Impact of effect on bone mineral densityJournal of Allergy and Clinical Immunology, 2006
- Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthmaAnnals of Allergy, Asthma & Immunology, 2006
- Has the cost-effectiveness of Xolair (omalizumab) been underestimated?Journal of Allergy and Clinical Immunology, 2005
- Lack of cost-effectiveness of omalizumabJournal of Allergy and Clinical Immunology, 2005
- Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthmaAllergy, 2004
- Steroid resistance in asthma: a major problem requiring novel solutions or a non-issue?Current Opinion in Pharmacology, 2004
- Association between preference-based health-related quality of life and asthma severityAnnals of Allergy, Asthma & Immunology, 2004
- Omalizumab is effective in the long-term control of severe allergic asthmaAnnals of Allergy, Asthma & Immunology, 2003
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001